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Purpose: The purpose of this study was to compare outcomes of subjects with open-angle 
glaucoma (OAG) not controlled on one medication who underwent either implantation of two 
iStent inject® trabecular micro-bypass devices or received medical therapy consisting of a fixed 
combination of latanoprost/timolol.
Patients and methods: Of 192 subjects who qualified for the study and were enrolled, 94 were 
randomized to surgery with implantation of two iStent inject® devices in the treated eye and 98 
to receive medical therapy.
Results: At the month 12 visit, 94.7% of eyes (89/94) in the stent group reported an unmedi-
cated intraocular pressure (IOP) reduction of $20% versus baseline unmedicated IOP, and 
91.8% of eyes (88/98) in the medical therapy group reported an IOP reduction $20% versus 
baseline unmedicated IOP. A 17.5% between-group treatment difference in favor of the iStent 
inject group was statistically significant (P=0.02) at the $50% level of IOP reduction. An 
IOP #18 mmHg was reported in 92.6% of eyes (87/94) in the iStent inject group and 89.8% 
of eyes (88/98) in the medical therapy group. Mean (standard deviation) IOP decreases from 
screening of 8.1 (2.6) mmHg and 7.3 (2.2) mmHg were reported in the iStent inject and medi-
cal therapy groups, respectively. A high safety profile was also noted in this study in both the 
iStent inject and medical therapy groups, as measured by stable best corrected visual acuity, 
cup-to-disc ratio, and adverse events.
Conclusion: These data show that the use of iStent inject is at least as effective as two medica-
tions, with the clinical benefit of reducing medication burden and assuring continuous treatment 
with full compliance to implant therapy as well as having a highly favorable safety profile.
Keywords: ab interno, intraocular pressure, trabecular bypass, OAG, IOP reduction
Introduction
Glaucoma, a debilitating and prevalent disease, is a leading cause of blindness 
worldwide. The management of glaucoma requires chronic, life-long treatment with 
a spectrum of therapeutic options, including medications, laser treatment, and surgi-
cal implants, with the common goal among these therapies of reducing intraocular 
pressure (IOP) to a targeted level, preventing loss of visual field due to excessive 
pressure on the optic nerve, and minimizing the impact on quality of life.  Limitations 
of currently available medical treatments can result in adverse events1 coupled with 
a lack of patient compliance. These factors have prompted the development of new 
therapies to preserve visual function by delivering a significant and continued decrease 
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of IOP without compromising patient safety. Use of stents 
to create a direct route from the anterior chamber to the 
Schlemm’s canal, thus bypassing the damaged trabecular 
meshwork, was researched by Spiegel et al.2 Further evo-
lution to this technique was employed in the research and 
development of micro-invasive glaucoma surgery (MIGS) 
using ab interno trabecular micro-bypass stents in mild-
to-moderate subjects with open-angle glaucoma (OAG). 
This procedure and use of the first-generation device, the 
Glaukos iStent®  Trabecular Micro-Bypass Stent (Glaukos 
 Corporation, Laguna Hills, CA, USA) was demonstrated to 
be safe and effective in a prospective, randomized, multi-
center US investigational device exemption clinical trial and 
summarized by Samuelson et al.3 Further validation of the 
device in longer term (up to 5 years) prospective, randomized 
trials described by Fea et al, Craven et al, and others have 
continued to demonstrate the benefits of a single iStent for 
the reduction of IOP and medication burden.4–8
Implantation of two stents per glaucomatous eye has been 
evaluated both in vitro and in clinical studies to investigate 
whether a further increase of outflow can be accomplished. 
Bahler et al demonstrated in vitro that increased outflow 
above and beyond that achieved with one stent is a viable 
option.9 A clinical study by Belovay et al indicated that 
multiple stents during cataract surgery resulted in a mean 
reduction in IOP of ,15 mmHg coupled with reduced medi-
cations through 1 year after implantation.10
To further enable implantation of multiple stents into 
Schlemm’s canal, a second-generation, smaller, and cone-
shaped design (iStent inject® Trabecular Micro-Bypass; 
Glaukos Corporation) and a modified injector preloaded 
with two iStent inject devices were developed. This system 
is now under study in a US pivotal trial. The study by Bahler 
et al of this newer generation device using a similar method 
as the previous perfusion-model study showed that the addi-
tion of a second stent further increased outflow facility to 
0.78±0.66 µL/minute/mmHg.11 Long-term in vivo studies 
are underway to determine long-term efficacy.
Combination glaucoma drugs enable the possibility 
of synergistic medical therapies for greater IOP-lowering 
effect.12–15 Although these drugs may offer IOP reduction 
with increased compliance over instillation of multiple types 
of medications, there are still disadvantages, including high 
cost, inconvenience, potential side effects such as corneal 
epithelial cell damage, and noncompliance. Taking into 
consideration the current interest in combination therapies 
and the usage of multiple stents for IOP-lowering effect, the 
clinical trial described in this report was proposed. This final 
report summarizes the safety and efficacy clinical results at 
1 year following treatment of 192 subjects randomized to 
receive either two iStent inject devices or two medications.
Materials and methods
study design
This trial, also known as the Second Line Study, was con-
ducted at eight investigational sites in six countries (Italy, 
Spain, Poland, Germany, United Kingdom, and Armenia). 
The study design was a prospective, randomized trial to 
compare outcomes of subjects with OAG not controlled on 
one medication who underwent either implantation of two 
iStent inject devices or received medical therapy consisting 
of a fixed combination of latanoprost/timolol (Xalacom®; 
Pfizer, New York, NY, USA). One-hundred and ninety-two 
subjects were enrolled and followed for 1 year after  treatment. 
Subjects using one ocular hypotensive medication, who, 
in the opinion of the investigator, required additional IOP 
lowering to control their OAG, were screened for the trial 
and were washed out of their current glaucoma medication 
in the study eye prior to randomization. This included a 
4-week washout for prostaglandin analogs and beta-blockers, 
or 2-week washout for alpha-adrenergic agonists and car-
bonic anhydrase inhibitors. Final enrollment criteria were 
assessed at the baseline visit. In order to qualify, subjects 
presented with a post-washout IOP between $22 mmHg 
and ,38 mmHg. Subjects were then randomized to receive 
either implantation of two GTS400 stents in the study eye 
or medical therapy (latanoprost/timolol). Other inclusion 
criteria included minimum best corrected visual acuity 
(BCVA) of 20/200 or better, scleral spur clearly visible by 
gonioscopy, able and willing to attend follow-up visits for 
1 year postoperatively, and informed consent.
Subjects were excluded if they were known nonresponders 
to latanoprost, had secondary glaucoma (with the exception 
of pseudoexfoliative and pigmentary), prior incisional glau-
coma surgery or procedure such as trabeculectomy shunt or 
collagen implant, cloudy cornea inhibiting gonioscopic view, 
signs of traumatic or uveitic, neovascular, or angle-closure 
glaucoma. Prior selective laser trabeculoplasty in the study 
eye was allowed as long as the procedure was not performed 
within 90 days prior to the screening visit.
Following the implantation of two stents or initiation of 
fixed medical therapy, depending on the group assignment, 
subjects followed an identical schedule of postoperative 
examinations. Evaluations occurred at day 1, month 1, 3, 6, 
9, and 12. IOP was measured between 8–11 am to control 
for diurnal variation in IOP.
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Figure 1 gTs400 istent inject® and g2-M-is injector.
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Figure 2 g2-M-is injector.
Table 1 subject accountability
Visit Two iStent inject® 
n
Two medications 
n
screening 94 98
Baseline 94 98
Day 1 94 88
Month 1 93 96
Month 3 94 95
Month 6 93 92
Month 9 94 92
Month 12 94 91
stent and surgical technique
Subjects randomized to surgery received two iStent inject 
devices. Each iStent inject model GTS400 is a single-piece 
heparin-coated, gamma-sterilized titanium stent (Figure 1). 
An area of reduced outside diameter midway along the 
device is designed to provide retention within the trabecular 
meshwork, while multiple outlet lateral lumens (four outflow 
orifices) are designed to provide an exit route for aqueous 
humor from the anterior chamber. The stent is symmetrically 
designed such that it may be used in either the left or right 
eye. Two GTS400 stents are preloaded in the G2-M-IS injec-
tor system (Figure 2). The injector is designed to deliver the 
stents automatically into Schlemm’s canal when activated 
by the surgeon. The portion of the injector that enters the 
eye is a 23-gauge stainless steel tube. The injector features 
a surgeon-activated release button on the housing, which is 
pressed to allow the stents to move over a small guiding trocar 
to exit the injector. Two iStent inject devices were implanted 
through the trabecular meshwork into Schlemm’s canal at 
the nasal position, separated by 2–3 clock hours. Following 
implantation of two iStent inject devices, subjects received 
topical postoperative anti-inflammatory and anti-infective 
medications for 4 weeks.
The study was initiated using the first generation G2-0 
injector, which allows for insertion of one stent at a time. 
Subsequently, the second-generation injector G2-M-IS 
system, which is able to hold two stents, was introduced to 
the study, thus providing the clinician the ability to insert 
multiple stents while entering the eye only once.
study outcomes and statistical analysis
Eff icacy measures included percentage of subjects 
who achieved an IOP reduction $20% versus baseline 
unmedicated IOP, percentage of subjects who achieved an 
IOP #18 mmHg, mean IOP at each study visit, and mean 
reduction in IOP. Safety measures assessed cup-to-disc (CD) 
ratio, BCVA, and incidence of adverse events.
For the proportional analyses such as IOP reduction $20% 
and IOP #18 mmHg, exact 95% confidence intervals based 
on a binomial distribution were calculated for the responder 
rates. For the iStent inject eyes, responders included eyes on 
no medication at Month 12. For both groups, a nonresponder 
assumption was used for missing data. Fisher’s exact test was 
used to compare the responder rates between the two study 
groups. For continuous variables such as mean IOP and IOP 
reduction, mean and standard deviation (SD) were provided. 
Statistical tests were performed using SAS® software version 
9.1.3 (SAS Institute Inc., Cary, NC, USA).
Results
Demographics, preoperative 
characteristics, and medical therapy
Subject accountability is shown in Table 1. Of the 
229 subjects who were screened for the trial, 192 qualified 
and were enrolled. As shown in Table 2, of the 192 subjects, 
94 underwent surgery with implantation of two iStent inject 
devices in the treated eye and 98 were randomized to receive 
medical therapy.
Demographics and subject characteristics were similar for 
both study arms (Table 2). Mean age for the iStent inject group 
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was 64.5±10.3 years versus 64.3±9.8 years for the group receiv-
ing medical therapy. Of the 94 subjects in the iStent inject group, 
61% were female and 39% were male versus 51% female and 
49% male for the medical therapy group. All subjects in both 
groups were Caucasian. The majority of eyes in both groups 
were phakic (98% versus 97% for the iStent inject and medica-
tion groups, respectively). No subjects enrolled in the trial had 
undergone prior selective laser trabeculoplasty. As an alternative 
to the use of Xalacom (latanoprost/timolol), eight subjects were 
administered with Duotrav® (travoprost/timolol; Alcon, Inc., 
Hünenberg, Switzerland), a medication similar to Xalacom in 
mechanism of action. Four eyes in the iStent inject group were 
taking medication at the month 12 examination.
Efficacy
At the month 12 visit, 94.7% of eyes (89/94) in the iStent 
inject group reported an unmedicated IOP reduction $20% 
versus baseline unmedicated IOP, and 91.8% of eyes (88/98) 
in the medical therapy group reported an IOP reduction 
$20% versus baseline unmedicated IOP (Figure 3). A 17.5% 
between-group treatment difference in favor of the iStent 
inject group was statistically significant (P=0.02) at the $50% 
level of IOP reduction. An IOP #18 mmHg was reported in 
92.6% of eyes (87/94) in the stent group and 89.8% of eyes 
(88/98) in the medical therapy group (Figure 4).
At month 12, mean IOP in the iStent inject group was 13.0 
(SD 2.3) mmHg versus 21.1 (SD 1.7) mmHg at screening 
and 25.2 (SD 1.4) mmHg at baseline. A mean IOP decrease 
from screening of 8.1 (SD 2.6) mmHg was reported in the 
consistent cohort of subjects followed through month 12 
(Table 3). For eyes in the medical therapy group, mean IOP 
at month 12 was 13.2 (SD 2.0) mmHg versus 20.7 (SD 1.7) 
mmHg at screening and 24.8 (SD 1.7) mmHg at baseline. 
A mean IOP decrease from screening of 7.3 (SD 2.2) mmHg 
was reported in the consistent cohort of subjects followed 
through month 12.
safety measurements
Vertical CD ratio data are provided in Table 4. The propor-
tion of subjects with a CD ratio increase or decrease from 
Table 2 Demographics
Two iStent inject® 
(N=94)
Two medications 
(N=98)
age (years)  
 Mean (sD) 64.5 (10.3) 64.3 (9.8)
 range 26–83 39–83
sex
 Male/female 37 (39%)/57 (61%) 48 (49%)/50 (51%)
race/ethnicity
 White 94 (100%) 98 (100%)
eye
 OD/Os 41 (44%)/53 (56%) 47 (48%)/51 (52%)
lens status
 Phakic/pseudophakic 92 (98%)/2 (2%) 95 (97%)/3 (3%)
Abbreviations: OD, right eye; Os, left eye; sD, standard deviation.
100
75
50
25
0
M12 IOP reduction ≥50% ≥40% ≥30% ≥20%
35.7
53.2
*P=0.02
iStent inject group
iStent inject group
(%, 95% CI)
2-med group
(%, 95% CI)
Medications group
80.9
75.5
93.6
88.8
94.7 91.8
53.2
(42.6, 63.6)
35.7
(26.3, 46.0)
80.9
(71.4, 88.2)
75.5
(65.8, 83.6)
93.6
(86.6, 97.6)
88.8
(80.8, 94.3)
94.7
(88.0, 98.3)
91.8
(84.5, 96.4)
Figure 3 Proportion of eyes with an M12 iOP reduction $50%, $40%, $30%, and $20%, respectively, for the istent inject eyes without medication versus the two 
medications group, with a nonresponder assumption for missing data. A between-group difference was significant (P=0.02) at the $50% level of iOP reduction.
Abbreviations: CI, confidence interval; IOP, intraocular pressure; M12, month 12.
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preoperative data at month 12 was similar within groups and 
between groups, and suggests that the CD ratio did not change 
over the 12-month timeframe. The CD ratio was maintained 
through month 12 in most eyes. The proportion of eyes with 
BCVA of 20/40 or better was 84% preoperatively versus 79% 
at month 12 in the iStent inject group and 87% preoperatively 
versus 84% at month 12 in the medication group. Five subjects 
in the iStent inject group and nine subjects in the medication 
group experienced a slight decrease in BCVA; however, this was 
anticipated in this population which included eyes with progres-
sion of preexisting cataract and other ocular problems.
adverse events and other  
postoperative observations
Ocular adverse events and other postoperative observations 
are summarized in Table 5. One adverse event was reported 
in the iStent inject group – one subject experienced IOP 
de compensation with an elevated IOP (48 mmHg). The 
subject was treated with medication and the IOP was low-
ered to 25 mmHg. One subject had one stent reported as not 
visible, which was resolved after neodymium-doped yttrium 
aluminum garnet laser treatment to remove an apparent 
obstruction. One subject reported soreness/discomfort that 
was resolved following treatment with nonsteroidal anti-
inflammatory medications. Two adverse events were reported 
in two subjects in the medical therapy group – mild burning 
of the eye (suspected intolerance to Xalacom) and suspected 
allergy to medication.
Discussion
A series of studies to treat OAG using the Glaukos micro-
bypass iStent technology as a sole procedure was under-
taken by the MIGS Study Group. The study group was 
comprised of surgeons from many countries. Unlike the 
present multicenter study, these MIGS surgeons performed 
the procedures at a single site on a homogeneous population 
in Armenia. One study in the series, to assess the implanta-
tion of two iStent devices in subjects with mild-to-moderate 
Table 3 Mean intraocular pressure and intraocular pressure change by visit – all eyes
IOP Screening Baseline washout Month 1 Month 3 Month 6 Month 9 Month 12
Two iStent inject (N=94)
iOP over time
 n 94 94 93 94 93 94 94
 Mean (sD) 21.1 (1.7) 25.2 (1.4) 13.3 (4.1) 12.8 (3.2) 12.7 (3.2) 12.9 (2.9) 13.0 (2.3)
iOP change from screening
 n 93 94 93 94 94
 Mean (sD) -7.7 (4.2) -8.3 (3.3) -8.5 (2.8) -8.2 (3.0) -8.1 (2.6)
iOP change from baseline
 n 93 94 93 94 94
 Mean (sD) -11.8 (4.2) -12.4 (3.4) -12.5 (3.2) -12.3 (3.0) -12.2 (2.5)
Two medications (N=98)
iOP over time
 n 98 98 96 95 91 92 90
 Mean (sD) 20.7 (1.7) 24.8 (1.7) 12.8 (2.6) 12.5 (2.8) 12.2 (2.2) 12.8 (2.9) 13.2 (2.0)
iOP change from screening
 n 96 95 91 92 90
 Mean (sD) -7.9 (2.9) -8.1 (2.6) -8.3 (2.4) -7.7 (2.8) -7.3 (2.2)
iOP change from baseline
 n 96 95 91 92 90
 Mean (sD) -12.0 (2.9) -12.3 (2.8) -12.6 (2.4) -11.9 (2.8) -11.6 (2.2)
Abbreviations: iOP, intraocular pressure; sD, standard deviation.
100
75
50
25
0
85.1 81.6
92.6 89.8
iStent inject group
Medications group
M12 IOP
iStent inject group
(%, 95% Cl)
2-med group
(%, 95% Cl)
≤15 mmHg ≤18 mmHg
85.1
(76.3, 91.6)
81.6
(72.5, 88.7)
92.6
(85.3, 97.0)
89.8
(82.0, 95.0)
Figure 4 Proportion of eyes with an M12 iOP #15 mmhg and #18 mmhg, 
respectively, for the istent inject eyes without medication versus the two-medications 
group, with a nonresponder assumption for missing data.
Abbreviations: CI, confidence interval; IOP, intraocular pressure; M12, month 12.
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OAG not controlled on one preoperative ocular hypotensive 
medication, reported an average IOP of 13.6 mmHg at 
1 year postoperatively without medication and without 
significant postoperative effects, demonstrating that earlier 
intervention of patients with mild-to-moderate OAG may 
potentially be a preferable alternative to chronic use of 
multiple medications.16 In another study, which assessed 
two-stent implantation in 41 moderate-to-advanced OAG 
phakic and pseudophakic patients not controlled on two 
medications preoperatively, all eyes achieved month 12 
IOP reduction $20% with reduction of one medication and 
month 12 IOP #18 mmHg with reduction of one medication. 
Mean IOP reduction .10 mmHg on one medication was 
sustained through 18 months.17
The Second Line Study, described in this report, was 
designed in recognition of the European Glaucoma Society 
guidelines that specify addition of a second medication in 
primary OAG prior to surgery.18 This pan-European, mul-
ticenter study considered surgery with a new MIGS device 
as an alternative to a second medication under a prospec-
tive, randomized study design of the iStent inject device 
versus a fixed combination of prostaglandin/beta-blocker. 
A significantly higher proportion of iStent inject eyes versus 
medication eyes achieved month 12 IOP reduction $50% 
versus baseline IOP. Mean IOP in the iStent inject group at 
1 year was 13.0 mmHg versus 13.2 mmHg in the medication 
group. Mean IOP decrease from baseline (12.2 mmHg in the 
iStent inject group versus 11.6 in the medication group) was 
reported. These data show that the use of iStent inject is at 
least as effective as two medications, with the clinical benefit 
of reducing medication burden and assuring continuous treat-
ment with full compliance to implant therapy.
A high iStent implant safety profile was also noted in this 
study, as measured by stable BCVA, CD ratio, and adverse 
events. The low rate of reported adverse events is consistent 
with work by Arriola-Villalobos on the first-generation stent, 
in which one eye experienced visual acuity loss due to macu-
lar degeneration and one eye required topical medication for 
increased IOP, in a series of 19 eyes with follow-up through a 
mean of 54 months.7 Fea et al’s series of ten iStent subjects 
and 14 control subjects followed for 56 months reported no 
adverse events in the treatment group and macular drusen in 
one subject in the control group.6
This study has several strengths, including that it is a 
multicenter study conducted in a large number of countries, 
which provides external validation of results. The use of 
trabecular micro-bypass stents versus ocular hypotensive 
medications to control IOP is an important development. 
Newer drugs, such as actin cytoskeleton agents or rho-
associated protein kinase inhibitors, are targeted to alter the 
compromised trabecular meshwork and improve outflow.19 
However, patient compliance with chronic, long-term use of 
topical medications and the associated side effects has been 
demonstrably poor and is always suspect. Noncompliance 
with medical therapy, leading to disease progression and 
eventually to blindness, may be preventable by implantation 
of this device.
Table 4 Vertical cup-to-disc ratio change from baseline
Month 1 Month 3 Month 6 Month 9 Month 12
Two iStents (N=94)
n 92 91 92 93 93
Better (decrease .0.2) 2 (2%) 0 (0%) 0 (0%) 1 (1%) 0 (0%)
no change (change within ±0.2) 89 (97%) 89 (98%) 91 (99%) 89 (96%) 90 (97%)
Worse (increase .0.2) 0 (0%) 1 (1%) 1 (1%) 2 (2%) 1 (1%)
n (missing) 0 2 0 0 0
Two medications (N=98)
n 94 93 92 91 89
Better (decrease .0.2) 1 (1%) 0 (0%) 2 (2%) 0 (0%) 1 (1%)
no change (change within ±0.2) 92 (98%) 92 (99%) 90 (98%) 91 (100%) 88 (99%)
Worse (increase .0.2) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
n (missing) 1 1 0 0 1
Table 5 Ocular adverse events and other postoperative 
observations
iStent inject  
group (N=94)
Medical therapy 
group (N=98)
eye burning 0 (0%) 1 (1%)
iOP decompensation 1 (1%) 0 (0%)
Medication allergy 0 (0%) 1 (1%)
One stent not visible  
(treated with nd:Yag laser)
1 (1%) 0 (0%)
soreness/discomfort 1 (1%) 0 (0%)
Abbreviations: iOP, intraocular pressure; nd:Yag, neodymium-doped yttrium 
aluminum garnet.
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There are several limitations in this work, including 
that it was not a masked study due to the disparate forms 
of therapy (surgery in one group, medication in the other 
group). Because of the qualifying IOP requirement, lower 
dispersion of IOP measurement data or regression to the 
mean may have occurred. However, these limitations are 
highly unlikely to have altered the findings that two iStent 
inject devices provide comparable benefits to combination 
medical therapy for OAG subjects.
Long-term follow-up studies are important in order to 
evaluate efficacy and adverse effects past a 1-year time-
frame. For example, long-term data from Craven et al,4 Fea 
et al,6 and Arriola-Villalobos et al7 on the first-generation 
iStent showed sustained IOP reduction and excellent safety 
through ,56 months postoperatively. Because the first- and 
second-generation trabecular micro-bypass devices are both 
based on the trabecular bypass principle,2 similar favorable 
long-term efficacy and safety of the iStent inject is expected. 
Future studies that can assess the use of the iStent inject for 
a timeframe .1 year are recommended to assess long-term 
findings. A future summary of patient questionnaire find-
ings from this study is also recommended as this report was 
limited to safety and efficacy clinical data. Furthermore, this 
study was limited to white patients only. As some patients, 
such as black patients, may exhibit higher resistance to 
glaucoma medical therapy, it is possible that trabecular 
micro-bypass stents may be of even greater benefit in some 
racial groups. It is recommended that future work expands 
the demographic population so that the benefit of the iStent 
inject can be further evaluated. In this study, stents were 
placed in the nasal quadrant because this area features the 
highest distribution of collector channels.20 The authors envi-
sion that future studies can examine optimum placement of 
stents near the opening of major collector channels using 
newer imaging technologies that can readily identify these 
physiological structures.21 Finally, although subjects in the 
medication group were instructed to follow the postopera-
tive medication regimen (and were provided eye drops at no 
cost to them), the authors relied on the subjects’ responses 
that they complied with the protocol-specified medication 
regimen as evidence that the subjects took their eye drops. 
However, the substantial IOP reduction after treatment sug-
gests strong compliance by the patients.
Conclusion
The favorable results of this third in a series of studies of the 
MIGS Study Group confirms that micro-invasive surgery 
using the iStent inject has the potential to be a valid alternative 
to medication for first-line therapy for mild-to-moderate OAG. 
The data presented in this publication represent the status 
of the patients 1 year after surgery; longer-term studies are 
underway. This study confirms that the iStent inject is a safe 
and effective implant procedure with a high benefit-to-risk 
profile and may be a preferable alternative to chronic use of 
multiple medications in subjects with OAG.
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